Coccidioidomycosis (Valley Fever)

Overview and Causative Organism
Endemic Zones and Epidemiology
Who Is at Risk
Pulmonary Disease
Extrapulmonary Dissemination
Erythema Nodosum and Desert Rheumatism
Diagnosis
Serology: IgM and IgG Testing
Treatment
Coccidioidal Meningitis
Key Research Papers
Featured Videos

Overview and Causative Organism

Coccidioidomycosis, commonly called Valley Fever, is a fungal infection caused by two closely related species: Coccidioides immitis and Coccidioides posadasii. Though geographically distinct, the two species produce identical disease in humans and cannot be differentiated clinically. C. immitis predominates in California's San Joaquin Valley and northwestern Mexico, while C. posadasii accounts for most infections in Arizona, New Mexico, Texas, and the rest of Central and South America.

What makes Coccidioides uniquely dangerous is its dimorphic life cycle. In soil, the fungus grows as a mold producing barrel-shaped arthroconidia — spores that break apart easily and become airborne. These arthroconidia are among the most infectious particles in mycology: a dose as low as a single spore is sufficient to cause infection in an animal model, and laboratory accidents involving live cultures have killed trained microbiologists. For this reason, Coccidioides is classified as a Biosafety Level 3 (BSL-3) pathogen, and cultures must never be opened on an open bench.

When inhaled, arthroconidia convert to the tissue form: large, round spherules, typically 20–80 micrometers in diameter, that fill with hundreds of endospores. When a mature spherule ruptures, each endospore can seed a new spherule at a distant site. This spherule-endospore cycle — unique to Coccidioides among all human pathogens — is pathognomonic when seen on histopathology. The host immune response determines whether infection stays confined to the lungs or disseminates to bone, skin, meninges, or viscera.

Back to Table of Contents

Endemic Zones and Epidemiology

Coccidioidomycosis is firmly rooted in the arid and semi-arid soils of the Western Hemisphere. The classic endemic zone spans the Sonoran Desert ecosystem: Arizona, southern California, southern New Mexico, west Texas, the northern Mexican states of Sonora and Baja California, and scattered pockets in Central and South America, including Venezuela and Argentina. Within the United States, Arizona carries the highest case burden, consistently accounting for more than 60% of all reported cases each year.

An estimated 150,000 new infections occur annually in the United States alone, though true incidence is almost certainly higher because the majority of infections are either asymptomatic or misdiagnosed as community-acquired pneumonia or influenza. Studies in highly endemic counties suggest that virtually the entire long-term population has been exposed by midlife.

The environmental trigger for spore release is critically important. Coccidioides thrives in alkaline, sandy desert soil with low organic content. The organism proliferates underground during brief wet periods, then desiccates into arthroconidia during drought. Wind, dust storms, soil disturbance from construction, military training, and agricultural work all release spores into the air. Large outbreaks have followed dust storms striking uninfected populations — including an infamous cluster among non-immune archaeology students excavating in an endemic area and a documented outbreak following a major earthquake in California.

Concerningly, the geographic range is expanding. Climate change is driving the endemic zone northward and eastward as rising temperatures and altered precipitation patterns create newly suitable soil conditions in states like Nevada, Utah, and parts of the Pacific Northwest. Cases are increasingly being reported outside the traditional Sonoran zone, and modeling studies suggest the endemic area could more than double by 2100 if warming trends continue unchecked.

Back to Table of Contents

Who Is at Risk

The single most important determinant of disease outcome is the host immune response. Roughly 60% of infected individuals never develop symptoms, and most of the remaining 40% experience only a self-limited respiratory illness. However, certain populations face dramatically elevated risks of severe or disseminated disease.

Pregnancy is the highest-risk physiological state for dissemination. Particularly in the third trimester, coccidioidomycosis can progress with terrifying speed to widespread disseminated disease. Both maternal and fetal mortality are high in untreated cases; the infection can cross the placenta and infect the newborn. All pregnant women in endemic areas should be counseled about the risk, and any respiratory illness during pregnancy in an endemic region should prompt serologic testing.

Immunocompromised patients are at severe risk. HIV infection — especially with CD4 counts below 250 cells/mm³ — dramatically increases the probability of dissemination and recurrence. Organ transplant recipients on immunosuppressive regimens, patients receiving high-dose corticosteroids, and patients on TNF-alpha inhibitors (used for rheumatoid arthritis, Crohn's disease, and psoriasis) are all at heightened risk. Infectious disease guidelines recommend baseline coccidioidal serology screening before starting biologic immunosuppressants in patients who live in or have lived in endemic areas.

Racial and ethnic background confers striking differences in dissemination risk. Individuals of Filipino ancestry and African Americans face approximately a 10-fold higher risk of dissemination compared to non-Hispanic Whites, even after controlling for socioeconomic variables and comorbidities. The mechanism is believed to be genetic, involving differences in innate immune recognition of fungal antigens, though the specific loci are still being characterized. Blood type B is also associated with increased risk of severe disease in some studies.

Other risk factors include diabetes mellitus (impairs macrophage killing of Coccidioides), lymphoma and other hematologic malignancies, and extreme age. Occupationally, agricultural workers, construction workers, military personnel stationed in the desert Southwest, and archaeologists have historically borne the highest exposures.

Back to Table of Contents

Pulmonary Disease

The lungs are the portal of entry and the primary site of disease. After inhalation, arthroconidia land in the small airways and alveoli, where they convert to spherules over the ensuing days. The incubation period is typically one to three weeks, though it can range from days to months depending on inoculum size and host immunity.

In approximately 60% of infected individuals, primary infection is completely asymptomatic and is only discovered incidentally through positive serology or a calcified pulmonary granuloma on imaging. Symptomatic primary coccidioidomycosis — the classic "Valley Fever" presentation — resembles an unusually severe influenza or community-acquired pneumonia:

Fever, often high and prolonged
Dry or productive cough
Pleuritic chest pain
Profound fatigue — perhaps the most characteristic feature; patients frequently describe being bedridden for weeks and unable to work for months
Night sweats and weight loss
Peripheral eosinophilia — elevated blood eosinophils are an important clue in any patient with pneumonia in an endemic area; this finding should prompt coccidioidal serology immediately
Hilar and mediastinal lymphadenopathy on chest imaging

Chest radiography and CT may show consolidation, pulmonary nodules, hilar adenopathy, or pleural effusion. Most symptomatic patients recover without treatment over weeks to months, though fatigue can linger for a year or more.

A subset of patients develop pulmonary complications that require specific management. The most distinctive is the thin-walled pulmonary cavity — a characteristic feature of coccidioidomycosis that contrasts with the thick-walled cavities more typical of Aspergillus or tuberculosis. These thin-walled cavities often resolve spontaneously over months to years. However, they can rupture, causing a bronchopleural fistula or pyopneumothorax — surgical emergencies requiring chest tube placement and, in many cases, thoracic surgery. Coccidioidal pulmonary nodules may persist indefinitely as "coin lesions," occasionally raising concern for malignancy and prompting biopsy.

Chronic progressive fibrocavitary coccidioidomycosis resembles post-primary tuberculosis, with upper-lobe infiltrates, cavitation, fibrosis, and progressive respiratory impairment. This form is more common in immunocompromised patients and diabetics, and typically requires prolonged antifungal therapy.

Back to Table of Contents

Extrapulmonary Dissemination

Dissemination occurs when spherules breach the lungs and seed distant organs via hematogenous spread. It complicates approximately 1–5% of all symptomatic infections in immunocompetent hosts, but rates are far higher in high-risk groups — approaching 50% or more in severely immunocompromised patients. Dissemination typically occurs within the first weeks to months after primary infection, although it can occur or recur years later if immunity wanes.

Skeletal dissemination is the most common form of extrapulmonary disease after meningitis. Coccidioides has a predilection for long bones, vertebrae, and bony prominences. Vertebral involvement (coccidioidal spondylitis) can mimic Pott's disease (spinal tuberculosis) and may cause vertebral collapse and spinal cord compression, requiring surgical stabilization. Bone lesions appear lytic on radiography and are confirmed by biopsy showing spherules.

Skin and soft tissue dissemination produces a range of lesions: verrucous (wart-like) papules and nodules, ulcers, and cold abscesses — fluctuant subcutaneous masses without overlying warmth or erythema, similar in appearance to scrofula from tuberculosis. Skin lesions typically occur on the face, particularly the nasolabial folds, and can also arise over bony prominences where underlying osteomyelitis has tracked outward through soft tissue. Skin biopsy showing spherules is diagnostic.

Visceral dissemination can involve virtually any organ — liver, spleen, kidney, adrenals, peritoneum, and lymph nodes — though these sites are less common than bone, skin, and meninges. Peritoneal coccidioidomycosis may present as chronic peritonitis with ascites. Genitourinary involvement can present as sterile pyuria.

Any patient with coccidioidomycosis who develops new pain in bones or joints, skin nodules, or neurological symptoms should be evaluated urgently for dissemination with imaging, lumbar puncture if meningitis is suspected, and repeat serology to assess complement fixation titers.

Back to Table of Contents

Erythema Nodosum and Desert Rheumatism

Among the distinctive early manifestations of symptomatic coccidioidomycosis is a syndrome known as "desert rheumatism" — a triad of erythema nodosum, polyarthritis, and fever occurring in the first few weeks of primary infection. This syndrome is caused not by direct fungal invasion of the skin and joints, but by the host's vigorous immune response to fungal antigens. It is an immunologic reaction, not dissemination.

Erythema nodosum presents as tender, red, raised nodules typically on the shins (anterior lower legs), occasionally extending to thighs and forearms. The lesions represent a panniculitis — inflammation of subcutaneous fat — driven by type IV (delayed-type) hypersensitivity. They resolve over weeks without specific treatment.

Coccidioidal polyarthritis resembles reactive arthritis: warm, swollen, painful joints, most often knees and ankles, without true joint infection. Like erythema nodosum, it resolves spontaneously.

Paradoxically, the presence of this immune-mediated syndrome carries a favorable prognostic significance. It indicates a robust Th1 immune response to the fungus — the same immune mechanism that clears the infection. Patients who develop erythema nodosum and desert rheumatism are at low risk of dissemination and typically recover completely without antifungal therapy.

The syndrome is considerably more common in White women than in men or in other racial groups, though the immunological basis for this demographic skew is not fully understood. Clinicians practicing in endemic areas learn to recognize this constellation of findings as nearly diagnostic of Valley Fever pending confirmatory serology.

Back to Table of Contents

Diagnosis

Accurate diagnosis of coccidioidomycosis requires a combination of clinical suspicion, epidemiological context, and laboratory confirmation. The disease is notoriously underdiagnosed: multiple studies have documented that symptomatic patients see an average of three to five physicians and wait more than six months before the correct diagnosis is made. The key is remembering to think of it — any pneumonia or prolonged flu-like illness in a patient who lives in or has recently visited an endemic area deserves coccidioidal testing.

Serology is the primary diagnostic tool for most patients (see next section). Culture of respiratory specimens, tissue, or CSF can confirm diagnosis but carries serious biohazard risk — Coccidioides mold colonies in culture release infectious arthroconidia and must be handled in a BSL-3 facility. Routine clinical microbiology labs should be notified whenever coccidioidomycosis is suspected so cultures can be handled safely.

Histopathology from biopsy tissue is highly specific when spherules with endospores are identified. Periodic acid-Schiff (PAS) and Grocott-Gomori methenamine silver (GMS) stains highlight the fungal cell wall. The spherule is pathognomonic — no other human pathogen produces this structure. Smaller immature spherules can be confused with non-encapsulated Cryptococcus or Blastomyces, requiring careful morphologic assessment.

Antigen detection (lateral flow immunoassay for coccidioidal galactomannan-like antigen in urine or serum) is useful in severe or disseminated disease and in immunocompromised patients who may not mount detectable antibody responses. Sensitivity is highest in disseminated disease.

Chest imaging (CT preferred over plain radiography) may show consolidation, nodules, hilar adenopathy, or cavities, but these findings are not specific. A pulmonary nodule in an endemic area — even one appearing on a CT scan ordered for an unrelated reason — should prompt coccidioidal serology before proceeding to bronchoscopy or biopsy.

Cerebrospinal fluid analysis in suspected meningitis shows lymphocytic or eosinophilic pleocytosis, elevated protein, low glucose, and positive coccidioidal complement fixation antibody in CSF. Eosinophils in CSF are rare in other conditions and should always raise coccidioidal meningitis as the leading diagnosis.

Back to Table of Contents

Serology: IgM and IgG Testing

Coccidioidal serology is the cornerstone of diagnosis and monitoring. Two antibody classes are measured, each with distinct timing, clinical meaning, and utility:

IgM antibodies (detected by tube precipitin [TP] test or IgM immunodiffusion [IDTP]) appear early — within the first one to three weeks of symptomatic infection — and peak at one to three months. They are the hallmark of acute primary infection. IgM titers do not correlate well with disease severity and are not useful for monitoring treatment response. They typically disappear by six months. A positive IgM in a patient with respiratory symptoms in an endemic area is highly suggestive of active primary coccidioidomycosis.

IgG antibodies (detected by complement fixation [CF] test or IgG immunodiffusion [IDCF]) appear later — typically four to twelve weeks after infection — and quantitative titers directly reflect disease burden and severity. This is the most important antibody for clinical management:

A rising IgG CF titer suggests progressive disease or impending dissemination
A titer of 1:32 or higher is associated with significantly increased risk of dissemination
A falling titer during treatment indicates a favorable response
A stable low titer (1:2 to 1:8) may persist for years after resolved infection without implying active disease
In coccidioidal meningitis, IgG CF antibody in CSF — not just serum — is a critical diagnostic finding

Modern enzyme immunoassays (EIA) detect both IgM and IgG simultaneously and have largely supplanted the older TP and CF tests at many laboratories, though CF titers remain the gold standard for quantitative monitoring. EIAs have higher sensitivity but somewhat lower specificity, occasionally producing false positives. Any positive EIA should be confirmed with immunodiffusion or CF testing before major clinical decisions are made.

Importantly, severely immunocompromised patients — including those with advanced HIV and organ transplant recipients — may fail to mount detectable antibody responses despite active disease. In these patients, antigen detection and culture become essential.

Back to Table of Contents

Treatment

Treatment decisions in coccidioidomycosis are driven by disease severity, site of infection, and host immune status. Not all infections require antifungal therapy.

Mild uncomplicated primary pulmonary coccidioidomycosis in an immunocompetent host often resolves without treatment. However, antifungal therapy is recommended to shorten illness and reduce the risk of complications in patients with:

Severe or prolonged symptoms (fever >4 weeks, weight loss >10%)
Extensive pulmonary infiltrates
Any high-risk host feature (pregnancy, immunocompromise, Filipino or African American ancestry, diabetes, CF titer ≥1:16)

First-line antifungal for most pulmonary and extrapulmonary non-meningeal disease: Fluconazole, typically 400–800 mg daily. Fluconazole is preferred for its oral bioavailability, tolerability, and decades of clinical experience. Itraconazole is an alternative, particularly for skeletal disease (some evidence suggests slightly better bone penetration). Treatment duration for pulmonary disease is typically three to six months, with response guided by clinical improvement and falling CF titers.

Disseminated non-meningeal coccidioidomycosis (bone, skin, soft tissue) requires prolonged therapy, often 12–24 months or longer, until CF titers have fallen substantially and clinical and radiographic improvement is sustained. Surgical debridement of osteomyelitis or drainage of cold abscesses is frequently required as an adjunct to antifungal therapy.

Severe or rapidly progressive disease: Amphotericin B (lipid formulation preferred for reduced nephrotoxicity) is used for patients with rapidly deteriorating pulmonary function, fulminant dissemination, or disease refractory to azoles. Amphotericin B is also the treatment of choice in pregnancy, as all azole antifungals are teratogenic and contraindicated throughout pregnancy. After delivery, azole therapy can be initiated, and many experts recommend lifelong suppressive fluconazole in women who had severe coccidioidomycosis during pregnancy.

Monitoring during treatment consists of serial complement fixation titers every two to three months, along with clinical and radiographic assessment. A falling titer is the most reliable indicator of treatment success. Stable or rising titers during therapy should prompt reassessment of diagnosis, adherence, and possible drug resistance (rare but reported with fluconazole).

Back to Table of Contents

Coccidioidal Meningitis

Coccidioidal meningitis is the most feared complication of Valley Fever, carrying a mortality rate approaching 100% if untreated and requiring lifelong antifungal suppression even with treatment. It typically develops within the first few months of primary infection but can present insidiously months to years later, particularly in immunocompromised patients or those who received inadequate primary therapy.

The clinical presentation is subacute to chronic, distinguishing it from bacterial meningitis. Patients develop gradually worsening headache, low-grade fever, neck stiffness, cranial nerve palsies (particularly CN VI, causing double vision), and altered mental status over days to weeks. Acute-onset severe meningismus is less common than in bacterial meningitis.

Lumbar puncture reveals the hallmark findings:

Eosinophilic pleocytosis — the presence of eosinophils in CSF is so unusual in other conditions that it should be considered coccidioidal meningitis until proven otherwise in any patient from an endemic area
Elevated protein
Low glucose (hypoglycorrhachia)
Positive IgG CF antibody in CSF — this is diagnostic; even a low titer in CSF is significant

MRI may show basilar meningeal enhancement, communicating hydrocephalus (a common complication requiring ventriculoperitoneal shunting), and occasionally parenchymal cerebritis or abscess.

Treatment is fluconazole 400–800 mg daily, continued for life. This is one of the few infections in medicine where the standard recommendation is truly indefinite therapy. Multiple studies have demonstrated that discontinuing fluconazole — even after years of treatment and clinical remission — results in relapse in nearly 100% of patients. The fungus persists in the meninges in a dormant state that cannot be eradicated by available antifungals.

For patients with fluconazole-refractory meningitis, options include high-dose fluconazole, voriconazole, posaconazole, or intrathecal amphotericin B — a technically demanding procedure requiring experienced neurology and infectious disease teams. Hydrocephalus should be managed with a ventriculoperitoneal shunt; repeated lumbar punctures for pressure management are inadequate for the long term.

Back to Table of Contents